Acta Pharmaceutica Sinica B· 2022Q1
Why 90% of clinical drug development fails and how to improve it?
- 1,627citations
- Q1SCImago
- 2022year
Short summary
A new framework, Structure-Tissue Exposure/Selectivity-Activity Relationship (STAR), is proposed to address the 90% failure rate in clinical drug development by rebalancing optimization from solely potency/specificity (SAR) to include tissue exposure/selectivity (STR).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Statistics and Probability
Statistics and ProbabilityMathematics